# Lenvatinib in Second Line Endometrial Carcinoma

> **NCT03005015** · PHASE2 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Endometrial Neoplasms

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT03005015
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2020-07
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** supporting company (Eisai) withdrew their interest
- **Last updated:** 2016-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03005015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03005015, "Lenvatinib in Second Line Endometrial Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03005015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*